Skip to main content

Advertisement

SpringerLink
Log in

Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries

  • Special Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

This paper describes the incidence of chemotherapy-induced nausea and vomiting (CINV) after highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer in six Asia Pacific countries.

Methods

Sequential adult patients naïve to chemotherapy and scheduled to receive at least two cycles of single-day HEC or MEC were enrolled in this prospective observational study. Patients completed the Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool on post-chemotherapy days 2 and 6 to record acute-phase (first 24 h) and delayed-phase (days 2–5) CINV.

Results

There were 648 evaluable patients (318 HEC, 330 MEC) from Australia (n = 74), China (153), India (88), Singapore (57), South Korea (151), and Taiwan (125). Mean (SD) patient age was 56 (12) and 58 % of patients were women; the most common primary cancers were breast (27 %), lung (22 %), and colon (20 %). Overall in cycle 1, complete response (no emesis or rescue antiemetics) was recorded by 69 % (95 % confidence interval (CI), 66–73) of all evaluable patients, with country percentages ranging from 55 to 78 % (p < 0.001). After HEC, no emesis was recorded by 75 % and no nausea by 38 % of patients. After MEC, 80 % had no emesis and 50 % no nausea. Acute-phase CINV was better controlled than delayed-phase CINV, and the control of nausea was the lowest of any CINV measure in all phases. In a CINV perception survey, physicians tended to overestimate emesis rate and underestimate nausea rate.

Conclusions

CINV remains a substantial problem, and country-specific information about CINV can be useful in developing strategies to improve outcomes for patients undergoing chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202. doi:10.1016/j.ejphar.2013.09.073

    Article  CAS  PubMed  Google Scholar 

  2. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482–2494. doi:10.1056/NEJMra0706547

    Article  CAS  PubMed  Google Scholar 

  3. Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20(2):113–121

    Article  CAS  PubMed  Google Scholar 

  4. Perwitasari DA, Atthobari J, Mustofa M, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, Nortier JW, Guchelaar HJ, Kaptein AA (2012) Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer. Int J Gynecol Cancer 22(1):139–145. doi:10.1097/IGC.0b013e318234f9ee

    Article  PubMed  Google Scholar 

  5. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472–4478

    Article  CAS  PubMed  Google Scholar 

  6. Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107–117. doi:10.1007/s00520-010-1073-9

    Article  PubMed Central  PubMed  Google Scholar 

  7. Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F (2013) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. doi:10.1016/j.jpainsymman.2013.06.012

    Google Scholar 

  8. Molassiotis A, Stamataki Z, Kontopantelis E (2013) Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support Care Cancer 21(10):2759–2767. doi:10.1007/s00520-013-1843-2

    Article  CAS  PubMed  Google Scholar 

  9. Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P (2011) Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 19(10):1549–1563. doi:10.1007/s00520-010-0982-y

    Article  PubMed  Google Scholar 

  10. Poon KS, Un MK, Low XH, Cheung YT, Yap KY, Chan A (2013) Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients. Pharmacoepidemiol Drug Saf 22(12):1345–1351. doi:10.1002/pds.3516

    Article  CAS  PubMed  Google Scholar 

  11. Yu Z, Liu W, Wang L, Liang H, Huang Y, Si X, Zhang H, Liu D (2009) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17(1):99–102. doi:10.1007/s00520-008-0503-4

    Article  PubMed  Google Scholar 

  12. Poon RT, Chow LW (1998) Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study. Br J Cancer 77(10):1683–1685

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113(3):529–535. doi:10.1007/s10549-008-9957-9

    Article  CAS  PubMed  Google Scholar 

  14. Chua DT, Sham JS, Au GK, Choy D, Kwong DL, Yau CC, Cheng AC (1996) The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial. Br J Clin Pharmacol 41(5):403–408

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Chua DT, Sham JS, Kwong DL, Kwok CC, Yue A, Foo YC, Chan R (2000) Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. Am J Clin Oncol 23(2):185–191

    Article  CAS  PubMed  Google Scholar 

  16. Ho CL, Su WC, Hsieh RK, Lin ZZ, Chao TY (2010) A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting. Jpn J Clin Oncol 40(4):294–301. doi:10.1093/jjco/hyp169

    Article  PubMed  Google Scholar 

  17. Maru A, Gangadharan VP, Desai CJ, Mohapatra RK, Carides AD (2013) A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis. Indian J Cancer 50(4):285–291. doi:10.4103/0019-509X.123580

    Article  CAS  PubMed  Google Scholar 

  18. Liau CT, Chu NM, Liu HE, Deuson R, Lien J, Chen JS (2005) Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes. Support Care Cancer 13(5):277–286. doi:10.1007/s00520-005-0788-5

    Article  PubMed  Google Scholar 

  19. Keefe D, Chan A, Kim H-K, Hsieh R-K, Yu S, Wang YC, Nicholls R, Burke TA (2014) Rationale and design of the Pan Australasian ChemoTherapy InduCed Emesis burden of illness study. Support Care Cancer. doi:10.1007/s00520-014-2374-1

  20. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103–109

    CAS  PubMed  Google Scholar 

  21. Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage 34(2):148–159

    Article  PubMed  Google Scholar 

  22. Yu S, Burke TA, Chan A, Kim H-K, Hsieh R-K, Hu X, Liang J-T, Banos A, Spiteri C, Keefe D (2014) Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a description of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer. doi:10.1007/s00520-014-2372-3

  23. Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992. doi:10.1093/annonc/mds021

    Article  CAS  PubMed  Google Scholar 

  24. Majem M, Moreno ME, Calvo N, Feliu A, Perez J, Mangues MA, Barnadas A (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19(12):1983–1990. doi:10.1007/s00520-010-1042-3

    Article  PubMed  Google Scholar 

  25. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261–2268

    Article  PubMed  Google Scholar 

  26. Erazo Valle A, Wisniewski T, Figueroa Vadillo JI, Burke TA, Martinez Corona R (2006) Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed. Curr Med Res Opin 22(12):2403–2410

    Article  PubMed  Google Scholar 

  27. Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA (2008) Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care (Engl) 17(5):444–453

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank all the investigators who participated in this study. This study was sponsored by Merck & Co., Inc. Medical writing and editorial assistance was provided by Elizabeth V. Hillyer, DVM. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ.

Conflict of interest

AC has received remuneration, served as a consultant/advisor, and received funding from Merck Sharp & Dohme (MSD). JD is an employee of OptumInsight Inc., the contract research organization that conducted the study. HJ and YPL are employees of MSD. TAB is an employee of Merck and may own stock or stock options. DMKK has served as a consultant/advisor for Merck, Pfizer, Soligenix, Entera, and Helsinn and has received funding from Entera and Helsinn. All remaining authors have declared no conflict of interest.

Author information

Authors and Affiliations

  1. Cancer Center, Mackay Memorial Hospital, Taipei, Taiwan

    Ruey Kuen Hsieh

  2. National University of Singapore, Singapore, Singapore

    Alexandre Chan

  3. St. Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea

    Hoon-Kyo Kim

  4. Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Shiying Yu

  5. Kyungpook National University Medical Center, Daegu, South Korea

    Jong Gwang Kim

  6. Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea

    Myung-Ah Lee

  7. OptumInsight, Inc., Stockholm, Sweden

    Johan Dalén

  8. Global Medical Affairs, Merck Sharp & Dohme, Seoul, South Korea

    Hun Jung

  9. Global Medical Affairs, Merck Sharp & Dohme, Singapore, Singapore

    Yan Ping Liu

  10. Global Health Outcomes, Merck Research Labs, One Merck Drive, Whitehouse Station, NJ, USA

    Thomas A. Burke

  11. Faculty of Health Sciences, University of Adelaide, Adelaide, Australia

    Dorothy M. K. Keefe

Authors
  1. Ruey Kuen Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandre Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hoon-Kyo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shiying Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jong Gwang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Myung-Ah Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johan Dalén
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hun Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yan Ping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Thomas A. Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dorothy M. K. Keefe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas A. Burke.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 281 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hsieh, R.K., Chan, A., Kim, HK. et al. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer 23, 263–272 (2015). https://doi.org/10.1007/s00520-014-2373-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2373-2

Keywords

Search

Navigation